Analysis of COVID-19 Patient Follow-Ups
Creators
- 1. Etimesgut Family Health Center, Ministry of Health, Ankara, Turkey.
- 2. Department of Family Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
- 3. Department of Family Medicine, Ankara Training and Education Hospital, University of Health Sciences, Ankara, Turkey.
- 4. Department of Internal Medicine, Division of Geriatric Medicine, Hacettepe University, Ankara, Turkey.
Description
Abstract
In this study, it was aimed to examine the follow-ups of patients diagnosed with COVID-19 during the pandemic process and to evaluate the relationship between the symptoms/disease characteristics of the individuals and their prognosis. The study was completed by retrospectively accessing the patient data with a diagnosis of COVID-19 between 01.04.2020 and 01.02.2021 using the archive scanning method. A total of 438 COVID-19 patients were included in the study. The study was completed by reaching the information questioned in the follow-up of the patients during the COVID-19 disease processes, information on the symptoms/disease characteristics and disease prognoses. Of the patients diagnosed with COVID-19, 49.3% were female and 50.7% were male. The hospitalization rate of the patients was found to be 12.3%. Hospitalization times of patients with cardiovascular disease, diabetes mellitus and respiratory system disease were found to be statistically significantly longer (p<0.001; p<0.001; p=0.045, respectively). There is a difference between the length of hospital stay of those with and without other chronic diseases (p=0.043). Hospitalization times were found to be significantly reduced in those using anticoagulants, steroids, and antibiotics. There was no difference between pneumococcal and influenza vaccination status and hospital stay. In this study, during the COVID-19 pandemic period, many parameters were examined in the follow-up of patients and conditions that could be related to the disease prognosis were evaluated. In the light of this information, it will be ensured that the prognosis of the people who will get COVID-19 disease will be predicted and the conditions that should be considered in the treatment and follow-up will be taken into consideration.
Özet
Bu çalışmada pandemi sürecinde COVID-19 tanısı almış hastaların takiplerinin incelenmesi ve kişilerin semptom/hastalık özellikleri ile prognozları arasındaki ilişkinin değerlendirilmesi amaçlanmıştır. Çalışma COVID-19 tanılı hasta bilgilerinin 01.04.2020 ile 01.02.2021 tarihleri arasındaki poliklinik verileri üzerinden arşiv tarama yöntemi kullanılarak retrospektif olarak incelenmesi ile tamamlandı. Çalışmaya 438 COVID-19 hastası dahil edildi. Hastaların COVID-19 hastalık süreçlerindeki takiplerinde sorgulanan bilgiler ve semptom/hastalık özelliklerine dair bilgiler incelenerek bu verilerin hastalık prognozları ile ilişkisi araştırıldı. COVID-19 tanılı izlem hastalarının %49.3’ü kadın, %50.7’si erkek idi. Hastaların hastanede yatma oranı %12.3 olarak bulundu. Kalp damar hastalığı, diabetes mellitus ve kronik solunum sistemi hastalığı olan kişilerde hastanede yatış sürelerinin istatistiksel açıdan anlamlı olarak daha uzun olduğu bulundu (sırasıyla p<0.001; p<0.001; p=0.045). Diğer kronik hastalığı olanlar ile olmayanların hastanede yatış süreleri arasında gözlemlenen farklılık da anlamlı idi (p=0.043). Antikoagülan, steroid ve antibiyotik tedavisi alanlarda hastane yatış sürelerinin anlamlı olarak azalmış olduğu bulunurken, pnömokok ve influenza aşısı olma durumu ve hastanede yatış süreleri arasında bir farklılık bulunmamıştır. COVID-19 pandemi döneminde hastaların takiplerinde birçok parametrenin incelendiği bu çalışmada hastalık prognozu ile ilişkili olabilecek durumlar değerlendirildi. Bu bilgiler ışığında COVID-19 hastalığına yakalanacak kişilerin hastalık prognozları hakkında öngörüde bulunularak tedavi ve takipte dikkat edilmesi gereken durumların göz önünde bulundurulması sağlanacaktır.
Notes
Files
lms.2022.10.z.pdf
Files
(424.1 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:3cdd62d10a393c3cce698eb8fafe6414
|
424.1 kB | Preview Download |
Additional details
References
- 1. Güner Ö, Buzgan T. The First Three Months of the COVID-19 Pandemic: The World Health Organization's Response. J Mol Virol Immunol 2021; 2(3): 86-101.
- 2. Xu K, Cai H, Shen Y, Ni Q, Chen Y, Hu S, et al. Management of corona virus disease-19 (COVID-19): the Zhejiang experience. Zhejiang Da Xue Xue Bao Yi Xue Ban 2020; 49(1): 147-57.
- 3. Republic of Turkey Ministry of Health, Ankara, Turkey. COVID-19 (SARS-CoV-2 Enfeksiyonu) Genel Bilgiler, Epidemiyoloji ve Tanı. Available at: https://covid19.saglik.gov.tr/Eklenti/39551/0/covid-19rehberigenelbilgilerepidemiyolojivetanipdf.pdf [Accessed October 08, 2021].
- 4. Republic of Turkey Ministry of Health, Ankara, Turkey. COVID-19 Bilgilendirme Platformu. Available at: https://covid19.saglik.gov.tr/ [Accessed October 08, 2021].
- 5. Yücesan B, Özkan Ö. COVID 19 Pandemi Sürecinin Sağlık Yönetimi Açısından Değerlendirilmesi. Avrasya Sağlık Bilimleri Dergisi 2020; 3(COVID-19): 134-9.
- 6. Dunlop C, Howe A, Li D, Allen LN. The coronavirus outbreak: the central role of primary care in emergency preparedness and response. BJGP Open 2020; 4(1): bjgpopen20X101041.
- 7. Zhu S, Li D. Sharing experience from Chinese General Practitioners to International colleagues on how to tackle COVID-19. APFM 2020; 18(1): 1-2.
- 8. Karaca B. Erişkin Yaş Grubunda COVID-19 Klinik Bulguları. J Biotechinol & Strategic Health Res 2020; 4: 85-90.
- 9. Uğraş Dikmen A, Kına M, Özkan S, İlhan MN. COVID-19 Epidemiyolojisi: Pandemiden Ne Öğrendik. J Biotechinol & Strategic Health Res 2020; 4: 29-36.
- 10. Larsen JR, Martin MR, Martin JD, Kuhn P, Hicks JB. Modeling the Onset of Symptoms of COVID-19. Front Public Health 2020; 8: 473.
- 11. Uğur Chousein EG, Çörtük M, Cınarka H, Tanrıverdi E, Turan D, Yıldırım BZ, et al. Is there any effect of smoking status on severity and mortality of hospitalized patients with COVID-19 pneumonia? Tuberk Toraks 2020; 68(4): 371-8.
- 12. Eastin C, Eastin T. Clinical Characteristics of Coronavirus Disease 2019 in China: Guan W, Ni Z, Hu Y, et al. N Engl J Med. 2020 Feb 28 [Online ahead of print] DOI: 10.1056/NEJMoa2002032. J Emerg Med 2020; 58(4): 711-2.
- 13. Zhao Q, Meng M, Kumar R, Wu Y, Huang J, Lian N, et al. The impact of COPD and smoking history on the severity of COVID-19: A systemic review and meta-analysis. J Med Virol 2020; 92(10): 1915-21.
- 14. Alqahtani JS, Oyelade T, Aldhahir AM, Alghamdi SM, Almehmadi M, Alqahtani AS, et al. Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis. PLoS One 2020; 15(5): e0233147.
- 15. Sandalcı B, Uyaroğlu OA, Sain Güven G. COVID-19'da kronik hastalıkların rolü, önemi ve öneriler. FLORA 2020; 25(2): 132-8.
- 16. Higgins V, Sohaei D, Diamandis EP, Prassas I. COVID-19: from an acute to chronic disease? Potential long-term health consequences. Crit Rev Clin Lab Sci 2021; 58(5): 297-310.
- 17. Kwok KO, Li KK, Wei WI, Tang A, Wong SYS, Lee SS. Editor's Choice: Influenza vaccine uptake, COVID-19 vaccination intention and vaccine hesitancy among nurses: A survey. Int J Nurs Stud 2021; 114: 103854.
- 18. Gostin LO, Salmon DA. The Dual Epidemics of COVID-19 and Influenza: Vaccine Acceptance, Coverage, and Mandates. JAMA 2020; 324(4): 335-6.
- 19. Güler S, Topuz İ, Ulusoy F. Covid-19 pandemisinde aile sağlığı merkezi çalışanlarının deneyimleri. Halk Sağlığı Hemşireliği Dergisi 2020; 2(3): 143-51.
- 20. Worby CJ, Chaves SS, Wallinga J, Lipsitch M, Finelli L, Goldstein E. On the relative role of different age groups in influenza epidemics. Epidemics 2015; 13: 10-6.
- 21. Kaya A. COVID-19 Course in Patients Receiving Pneumococcal Vaccine. Konuralp Medical Journal 2021; 13(S1): 390-4.
- 22. Gür A, Ekmekyapar M, Şahin L. The relationship between AB0 blood groups and COVID-19. J Surg Med 2020; 4(11): 956-9.
- 23. Zhao J, Yang Y, Huang H, Li D, Gu D, Lu X, et al. Relationship Between the ABO Blood Group and the Coronavirus Disease 2019 (COVID-19) Susceptibility. Clin Infect Dis 2021; 73(2): 328-31.
- 24. Fan Q, Zhang W, Li B, Li DJ, Zhang J, Zhao F. Association Between ABO Blood Group System and COVID-19 Susceptibility in Wuhan. Front Cell Infect Microbiol. 2020 Jul 21; 10: 404.
- 25. Gérard C, Maggipinto G, Minon JM. COVID-19 and ABO blood group: another viewpoint. Br J Haematol 2020; 190(2): e93-e94.